EP4426437A4 - Methods for treating cancer and increasing the efficacy of bispecific BCMAXCD3 antibodies - Google Patents

Methods for treating cancer and increasing the efficacy of bispecific BCMAXCD3 antibodies

Info

Publication number
EP4426437A4
EP4426437A4 EP22891008.9A EP22891008A EP4426437A4 EP 4426437 A4 EP4426437 A4 EP 4426437A4 EP 22891008 A EP22891008 A EP 22891008A EP 4426437 A4 EP4426437 A4 EP 4426437A4
Authority
EP
European Patent Office
Prior art keywords
bcmaxcd3
bispecific
antibodies
efficacy
increasing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22891008.9A
Other languages
German (de)
French (fr)
Other versions
EP4426437A1 (en
Inventor
Jenna Goldberg
Jagoda Jasielec
Raluca Verona
Brendan Weiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of EP4426437A1 publication Critical patent/EP4426437A1/en
Publication of EP4426437A4 publication Critical patent/EP4426437A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP22891008.9A 2021-11-03 2022-11-02 Methods for treating cancer and increasing the efficacy of bispecific BCMAXCD3 antibodies Pending EP4426437A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163275368P 2021-11-03 2021-11-03
US202163288279P 2021-12-10 2021-12-10
US202263348036P 2022-06-02 2022-06-02
PCT/US2022/079147 WO2023081705A1 (en) 2021-11-03 2022-11-02 Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies

Publications (2)

Publication Number Publication Date
EP4426437A1 EP4426437A1 (en) 2024-09-11
EP4426437A4 true EP4426437A4 (en) 2025-09-17

Family

ID=86242021

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22891008.9A Pending EP4426437A4 (en) 2021-11-03 2022-11-02 Methods for treating cancer and increasing the efficacy of bispecific BCMAXCD3 antibodies

Country Status (9)

Country Link
US (2) US12098210B2 (en)
EP (1) EP4426437A4 (en)
JP (1) JP2024540054A (en)
KR (1) KR20240099376A (en)
AU (1) AU2022380722A1 (en)
CA (1) CA3237357A1 (en)
IL (1) IL312503A (en)
MX (1) MX2024005392A (en)
WO (1) WO2023081705A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023524875A (en) * 2020-05-11 2023-06-13 ヤンセン バイオテツク，インコーポレーテツド Methods for treating multiple myeloma
WO2024044548A1 (en) * 2022-08-23 2024-02-29 Janssen Biotech, Inc. Teclistamab for the treatment of multiple myeloma
TW202517293A (en) * 2023-07-07 2025-05-01 美商再生元醫藥公司 Stabilized formulations containing anti-bcma x anti-cd3 bispecific antibodies
WO2025096717A1 (en) * 2023-11-01 2025-05-08 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2025094107A1 (en) * 2023-11-01 2025-05-08 Janssen Biotech, Inc. Methods for treating high-risk smoldering multiple myeloma
WO2025240287A1 (en) * 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Methods of treating light chain amyloidosis with bispecific bcma x cd3 antibodies
WO2025243241A1 (en) * 2024-05-23 2025-11-27 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2026012294A1 (en) * 2024-07-09 2026-01-15 深圳虹信生物科技有限公司 Drug, method, and use for treating diseases caused by autoantibody production resulting from excessive proliferation of b cells
WO2026059923A1 (en) * 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bcma inhibitors in combination with an immunomodulator
WO2026059919A1 (en) * 2024-09-10 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bcma inhibitors in combination with cd38 inhibitors
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200190205A1 (en) * 2018-05-16 2020-06-18 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
PT1024191E (en) 1991-12-02 2008-12-22 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
ES2156149T3 (en) 1992-12-04 2001-06-16 Medical Res Council MULTIVALENT AND MULTI-SPECIFIC UNION PROTEINS, ITS MANUFACTURE AND USE.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
CA2635352C (en) 1997-06-13 2012-09-11 Genentech, Inc. Stabilized antibody formulation
PT1015576E (en) 1997-09-16 2005-09-30 Egea Biosciences Llc METHOD FOR COMPLETE CHEMICAL SYNTHESIS AND ASSEMBLY OF GENES AND GENOME
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2001024812A1 (en) 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
WO2002066516A2 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
CA2563432A1 (en) 2004-04-16 2005-12-01 Genentech, Inc. Method for augmenting b cell depletion
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
JP5225069B2 (en) 2005-03-23 2013-07-03 ゲンマブ エー／エス Antibodies against CD38 for the treatment of multiple myeloma
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DE102005028778A1 (en) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Multi-layer foil, useful for lining a flexible container, comprises a barrier layer, a stretch-poor plastic layer, an antistatic plastic layer and a layer containing a safe material for food
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
CA2625681C (en) 2005-10-12 2016-08-02 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
PT1999154E (en) 2006-03-24 2013-01-24 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007117600A2 (en) 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
JP2009541275A (en) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス Production of bispecific antibodies
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
MX2009010611A (en) 2007-04-03 2010-03-26 Micromet Ag Cross-species-specific bispecific binders.
RS53008B2 (en) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Cross-species-specific cd3-epsilon binding domain
RU2769948C2 (en) 2007-04-03 2022-04-11 Эмджен Рисерч (Мьюник) Гмбх Cd3-epsilon-binding domain with interspecific specificity
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
CA2720682A1 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20110293619A1 (en) 2008-10-01 2011-12-01 Micromet Ag CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
EP2352765B1 (en) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
DK2352763T4 (en) 2008-10-01 2022-10-17 Amgen Res Munich Gmbh BISPECIFIC SINGLE CHAIN ANTIBODIES WITH SPECIFICITY FOR HIGH MOLECULAR TARGET ANTIGENS
ES2705714T3 (en) 2008-10-31 2019-03-26 Janssen Biotech Inc Methods and uses of domain of Fibronectina type III based on structures of compositions
BRPI1008532B1 (en) 2009-02-12 2021-12-14 Janssen Biotech, Inc ISOLATED PROTEIN FRAMEWORK, METHOD FOR BUILDING AN ISOLATED PROTEIN FRAMEWORK LIBRARY, ISOLATED NUCLEIC ACID MOLECULE, ISOLATED NUCLEIC ACID VECTOR, BACTERIAL OR FUNGUS HOST CELL, COMPOSITION, MEDICAL DEVICE AND MANUFACTURING ARTICLE FOR PRODUCT USE IN HUMAN BEINGS
MX341884B (en) 2009-03-10 2016-09-07 Biogen Ma Inc Anti-bcma antibodies.
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
HRP20241208T1 (en) 2010-04-20 2024-11-22 Genmab A/S HETERODIMER PROTEINS CONTAINING FC FRAGMENT OF ANTIBODIES AND PROCEDURES FOR THEIR PRODUCTION
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
ES2758994T3 (en) 2010-11-05 2020-05-07 Zymeworks Inc Stable heterodimeric antibody design with mutations in the Fc domain
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
KR101972446B1 (en) 2011-05-27 2019-04-25 글락소 그룹 리미티드 Bcma(cd269/tnfrsf17)-binding proteins
CA2880791A1 (en) 2011-08-03 2013-02-07 Children's Medical Center Corporation A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
BR112014010580B1 (en) 2011-11-04 2021-01-12 Zymeworks, Inc. isolated heteromultimeric fc construct, composition, use of an isolated heteromultimeric fc construct, nucleic acid composition and method for expressing the isolated heteromultimeric fc construct
TWI679212B (en) 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
RS60499B1 (en) 2011-12-20 2020-08-31 Medimmune Llc Modified polypeptides for bispecific antibody scaffolds
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
JP6509724B2 (en) 2012-04-20 2019-05-08 アプティーボ リサーチ アンド デベロップメント エルエルシー CD3 binding polypeptide
RU2015117393A (en) 2012-10-08 2016-12-10 Роше Гликарт Аг Deprived fc antibodies containing two Fab fragments, and methods for their use
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
TW201425336A (en) 2012-12-07 2014-07-01 Amgen Inc BCMA antigen binding proteins
PT2931030T (en) 2012-12-14 2020-08-03 Open Monoclonal Tech Inc POLYNUCLEOTIDES THAT CODE RODENT ANTIBODIES WITH HUMAN IDIOTYPES AND ANIMALS THAT UNDERSTAND THEM
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
CN113005091A (en) 2013-02-06 2021-06-22 细胞基因公司 Modified T lymphocytes with improved specificity
AR095374A1 (en) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh UNION MOLECULES FOR BCMA AND CD3
JP6594855B2 (en) 2013-03-15 2019-10-23 ゼンコア インコーポレイテッド Heterodimeric protein
GB201317928D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Molecule
TWI703159B (en) 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma-specific therapeutic antibodies and their uses
MX2018002043A (en) 2015-08-17 2018-07-06 Janssen Pharmaceutica Nv ANTI-BCMA ANTIBODIES, BSPECIFIC ANTIGEN-BINDING MOLLICULES THAT BIND BCMA AND CD3, AND USES THEREOF.
US10882918B2 (en) 2016-09-30 2021-01-05 Hoffmann-La Roche Inc. Bispecific T cell activating antigen binding molecules
JP7267914B2 (en) 2016-11-02 2023-05-02 エンクマフ エスアーエールエル Bispecific antibodies to BCMA and CD3 and immunotherapeutic agents used in combination to treat multiple myeloma
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
KR102870868B1 (en) * 2018-06-01 2025-10-15 노파르티스 아게 Binding molecules for BCMA and uses thereof
US20220003772A1 (en) 2018-10-31 2022-01-06 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2020194243A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with lenalidomide and dexamethasone
CN119679936A (en) * 2019-06-24 2025-03-25 诺华股份有限公司 Dosing regimens and combination therapies for multispecific antibodies targeting B cell maturation antigens
WO2021092060A1 (en) 2019-11-05 2021-05-14 Engmab Sarl Methods of treatment
WO2021091978A1 (en) 2019-11-05 2021-05-14 Celgene Corporation Uses of anti-bcma chimeric antigen receptors
CN114929343B (en) 2019-12-06 2025-03-18 瑞泽恩制药公司 Methods for treating multiple myeloma using bispecific anti-BCMA x anti-CD3 antibodies
JP2023524875A (en) * 2020-05-11 2023-06-13 ヤンセン バイオテツク，インコーポレーテツド Methods for treating multiple myeloma
TW202309522A (en) 2021-05-11 2023-03-01 美商健生生物科技公司 Methods and compositions for monitoring the treatment of relapsed and/or refractory multiple myeloma
EP4347039A1 (en) 2021-05-28 2024-04-10 Janssen Biotech, Inc. Bcma as a target for t cell redirecting antibodies in b cell lymphomas
KR20240099432A (en) 2021-11-10 2024-06-28 얀센 바이오테크 인코포레이티드 Stable formulation containing bispecific BCMA/CD3 antibody

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200190205A1 (en) * 2018-05-16 2020-06-18 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "NCT04108195: A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma", CLINICALTRIALS.GOV, 7 October 2021 (2021-10-07), XP093296811, Retrieved from the Internet <URL:https://clinicaltrials.gov/study/NCT04108195?tab=history&a=20#version-content-panel> *
FRERICHS KRISTINE A. ET AL: "Preclinical Activity of JNJ-7957, a Novel BCMAxCD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab", CLINICAL CANCER RESEARCH, vol. 26, no. 9, 1 May 2020 (2020-05-01), pages 2203 - 2215, XP055826554, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-19-2299 *
See also references of WO2023081705A1 *

Also Published As

Publication number Publication date
CA3237357A1 (en) 2023-05-11
WO2023081705A1 (en) 2023-05-11
JP2024540054A (en) 2024-10-31
US20230272102A1 (en) 2023-08-31
AU2022380722A1 (en) 2024-06-20
US12098210B2 (en) 2024-09-24
MX2024005392A (en) 2024-08-06
KR20240099376A (en) 2024-06-28
US20250109211A1 (en) 2025-04-03
IL312503A (en) 2024-07-01
EP4426437A1 (en) 2024-09-11

Similar Documents

Publication Publication Date Title
EP4426437A4 (en) Methods for treating cancer and increasing the efficacy of bispecific BCMAXCD3 antibodies
EP3999548A4 (en) CLAUDIN18 ANTIBODIES AND METHODS OF TREATMENT OF CANCER
EP4034138A4 (en) COMPOSITIONS AND METHODS FOR TREATING BLOOD CANCER
EP4376886A4 (en) METHODS FOR TREATING CANCER
EP4127722A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
EP4376959A4 (en) Methods and compositions for treating KRAS-mutant cancer
EP4097486A4 (en) COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCER
EP4003351A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP4172215A4 (en) ANTI-NME ANTIBODIES AND METHODS FOR TREATING CANCER OR CANCER METASTASIS
EP3965896A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
EP4323351A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP4412613A4 (en) METHODS FOR THE TREATMENT OF CANCER AND TUMORS
EP4499625A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
EP3966208A4 (en) COMPOUNDS AND METHODS FOR TREATING CANCER
EP3576766A4 (en) CYCLIN-G1 INHIBITORS AND RELATED METHODS FOR TREATING CANCER
EP4308160A4 (en) Method for treating gynaecological cancer using combination therapy with multispecific anti-MUC16-X CD3 antibodies and VEGF inhibition
EP4114411A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PANCREATIC CANCER
EP4259166A4 (en) METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
EP4204097A4 (en) METHODS FOR TREATING CANCER
EP4114864A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3983014A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3999065A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3962896A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
EP3902917A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
EP3886887A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240603

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40115754

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61P0035000000

Ipc: C07K0016280000

A4 Supplementary search report drawn up and despatched

Effective date: 20250818

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101AFI20250811BHEP

Ipc: A61P 35/00 20060101ALI20250811BHEP

Ipc: A61K 39/395 20060101ALI20250811BHEP